{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:06:37Z","timestamp":1789002397503,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neuropharm.2021.108694","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:54:20Z","timestamp":1625637260000},"page":"108694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-8287","authenticated-orcid":false,"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Skaggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neurobiolaging.2014.10.008","article-title":"Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice","volume":"36","author":"Morales-Garcia","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108694_bib2","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1021\/jm201720d","article-title":"Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds","volume":"55","author":"Redondo","year":"2012","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.neuropharm.2021.108694_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/cn300105c","article-title":"Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice","volume":"3","author":"Redondo","year":"2012","journal-title":"ACS Chem. Neurosci."},{"issue":"19","key":"10.1016\/j.neuropharm.2021.108694_bib4","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1016\/j.bmcl.2012.07.077","article-title":"Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson's disease model","volume":"22","author":"Banerjee","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2021.108694_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13195-018-0352-4","article-title":"Amyloid \u03b2-induced impairments on mitochondrial dynamics, hippocampal neurogenesis, and memory are restored by phosphodiesterase 7 inhibition","volume":"10","author":"Bartolome","year":"2018","journal-title":"Alzheimer's Res. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108694_bib6","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2021.108694_bib7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1570159X17666181127125704","article-title":"Current drugs and potential future neuroprotective compounds for Parkinson's disease","volume":"17","author":"Carrera","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108694_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cmdc.200900043","article-title":"Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors","volume":"4","author":"Casta\u00f1o","year":"2009","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108694_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1210\/mend.14.9.0534","article-title":"Phosphodiesterases and cyclic nucleotide signaling in endocrine cells","volume":"14","author":"Conti","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.neuropharm.2021.108694_bib10","series-title":"The Use of PDE7 Inhibitors for the Treatment of Movement Disorders","author":"Corp","year":"2008"},{"key":"10.1016\/j.neuropharm.2021.108694_bib11","series-title":"Use of Quinazoline Derivatives for Neurodegenerative Diseases","author":"CSIC","year":"2010"},{"issue":"20","key":"10.1016\/j.neuropharm.2021.108694_bib12","doi-asserted-by":"crossref","first-page":"8590","DOI":"10.1021\/jm501090m","article-title":"Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors","volume":"57","author":"Garc\u00eda","year":"2014","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108694_bib13","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1073\/pnas.101131098","article-title":"T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3","volume":"98","author":"Glavas","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bph.12308","article-title":"Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis","volume":"170","author":"Gonz\u00e1lez-Garc\u00eda","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"26","key":"10.1016\/j.neuropharm.2021.108694_bib15","doi-asserted-by":"crossref","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","article-title":"Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart","volume":"272","author":"Han","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/geno.1997.5168","article-title":"Assignment of the mouse Pde7A gene to the proximal region of chromosome 3 and of the human PDE7A gene to chromosome 8q13","volume":"48","author":"Han","year":"1998","journal-title":"Genomics"},{"issue":"22","key":"10.1016\/j.neuropharm.2021.108694_bib17","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1074\/jbc.M601333200","article-title":"Jun 2. PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C","volume":"281","author":"Han","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108694_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1073\/pnas.97.1.472","article-title":"Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase","volume":"97","author":"Hetman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.biopsych.2009.08.030","article-title":"Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches","volume":"67","author":"Ikeda","year":"2010","journal-title":"Biol. Psychiatr."},{"issue":"11","key":"10.1016\/j.neuropharm.2021.108694_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1358\/dot.2010.46.11.1521831","article-title":"Roflumilast for COPD","volume":"46","author":"Izquierdo","year":"2010","journal-title":"Drugs Today"},{"issue":"7","key":"10.1016\/j.neuropharm.2021.108694_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2174\/0929867324666170116125159","article-title":"PDE7-Selective and dual inhibitors: advances in chemical and biological research","volume":"24","author":"Jankowska","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108694_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2012.07.050","article-title":"Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain","volume":"525","author":"Johansson","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108694_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108694_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108694_bib25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2012.06.032","article-title":"Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL\/6J mice","volume":"64","author":"Lipina","year":"2013","journal-title":"Neuropharmacology"},{"issue":"35","key":"10.1016\/j.neuropharm.2021.108694_bib26","doi-asserted-by":"crossref","first-page":"24145","DOI":"10.1074\/jbc.M802278200","article-title":"Phosphorylation of the cAMP-dependent protein kinase (PKA) regulatory subunit modulates PKA-AKAP interaction, substrate phosphorylation, and calcium signaling in cardiac cells","volume":"283","author":"Manni","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2021.108694_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jchemneu.2016.12.001","article-title":"Mar. A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice","volume":"80","author":"Mart\u00edn-\u00c1lvarez","year":"2017","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2021.108694_bib28","doi-asserted-by":"crossref","first-page":"107357","DOI":"10.1016\/j.nlm.2020.107357","article-title":"Pharmacological inhibition of phosphodiesterase 7 enhances consolidation processes of spatial memory","volume":"177","author":"McQuown","year":"2021","journal-title":"Neurobiol. Learn. Mem."},{"issue":"18","key":"10.1016\/j.neuropharm.2021.108694_bib29","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00018-013-1340-2","article-title":"Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival","volume":"70","author":"Medina-Rodr\u00edguez","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108694_bib30","doi-asserted-by":"crossref","first-page":"43545","DOI":"10.1038\/srep43545","article-title":"Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis","volume":"7","author":"Medina-Rodr\u00edguez","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108694_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1021\/acsptsci.9b00068","article-title":"Nov 14. Remyelination pharmacotherapy investigations highlight diverse mechanisms underlying multiple sclerosis progression","volume":"2","author":"Melchor","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"17","key":"10.1016\/j.neuropharm.2021.108694_bib32","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1111\/bph.13192","article-title":"Sep. PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis","volume":"172","author":"Mestre","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.neuropharm.2021.108694_bib33","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1016\/S0021-9258(18)31474-1","article-title":"Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae","volume":"268","author":"Michaeli","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/syn.1043","article-title":"Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs","volume":"40","author":"Mir\u00f3","year":"2001","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017240","article-title":"Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease","volume":"6","author":"Morales-Garcia","year":"2011","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108694_bib36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5966\/sctm.2014-0277","article-title":"Phosphodiesterase 7 inhibition induces dopaminergic neurogenesis in hemiparkinsonian rats","volume":"4","author":"Morales-Garcia","year":"2015","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib37","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/stem.2480","article-title":"Phosphodiesterase 7 inhibition activates adult neurogenesis in hippocampus and subventricular zone in vitro and in Vivo","volume":"35","author":"Morales-Garcia","year":"2017","journal-title":"Stem Cell."},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s12035-019-01745-z","article-title":"Feb. Phosphodiesterase 7 regulation in cellular and rodent models of Parkinson's disease","volume":"57","author":"Morales-Garcia","year":"2020","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12311-015-0696-2","article-title":"Emotion and theory of mind in schizophrenia-investigating the role of the cerebellum","volume":"15","author":"Mothersill","year":"2016","journal-title":"Cerebellum"},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108694_bib40","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.3390\/ijms22063206","article-title":"Improved controlled release and brain penetration of the small molecule S14 using PLGA nanoparticles","volume":"22","author":"Nozal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108694_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/978-3-642-17969-3_17","article-title":"Phosphodiesterase inhibitors in the treatment of inflammatory diseases","volume":"204","author":"Page","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108694_bib42","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1021\/jm201463v","article-title":"5-imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3","volume":"55","author":"Palomo","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108694_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015937","article-title":"PDE 7 inhibitors: new potential drugs for the therapy of spinal cord injury","volume":"6","author":"Paterniti","year":"2011","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.neuropharm.2021.108694_bib44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ejps.2012.01.007","article-title":"5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase kinase 3\u03b2 (GSK-3\u03b2) and phosphodiesterase 7 (PDE7) inhibitors: determination of blood-brain barrier penetration and binding to human serum albumin","volume":"45","author":"P\u00e9rez","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci.: official journal of the European Federation for Pharmaceutical Sciences"},{"issue":"9","key":"10.1016\/j.neuropharm.2021.108694_bib45","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.neurobiolaging.2013.03.011","article-title":"Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer's disease","volume":"34","author":"Perez-Gonzalez","year":"2013","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/j.neuropharm.2021.108694_bib46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0014-4886(03)00042-6","article-title":"Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization","volume":"182","author":"P\u00e9rez-Torres","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108694_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2012.05.050","article-title":"Synaptic changes in Alzheimer's disease and its models","volume":"251","author":"Pozueta","year":"2013","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.neuropharm.2021.108694_bib48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2011.10.040","article-title":"(c). Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model","volume":"47","author":"Redondo","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108694_bib49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.neuroscience.2005.01.050","article-title":"Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain","volume":"132","author":"Reyes-Irisarri","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2021.108694_bib50","doi-asserted-by":"crossref","first-page":"112854","DOI":"10.1016\/j.ejmech.2020.112854","article-title":"New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases","volume":"209","author":"Ru\u010dilov\u00e1","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1006\/bbrc.2000.2661","article-title":"Identification of human PDE7B, a cAMP-specific phosphodiesterase","volume":"271","author":"Sasaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"Pt 2","key":"10.1016\/j.neuropharm.2021.108694_bib52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bj3610211","article-title":"Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation","volume":"361","author":"Sasaki","year":"2002","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2174\/1573409914666181003151528","article-title":"Synthesis, anti-inflammatory activity and docking studies of some newer 1,3-Thiazolidine-2,4-dione derivatives as dual inhibitors of PDE4 and PDE7","volume":"15","author":"Sharma","year":"2019","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1471-4159.2011.07581.x","article-title":"Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease","volume":"120","author":"Sheng","year":"2012","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.neuropharm.2021.108694_bib55","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/mol.104.002246","article-title":"Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes","volume":"66","author":"Smith","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"26","key":"10.1016\/j.neuropharm.2021.108694_bib56","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1471-4159.2012.07866.x","article-title":"The new iminothiadiazole derivative VP1.14 ameliorates hippocampal damage after an excitotoxic injury","volume":"122","author":"Sus\u00edn","year":"2012","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.neuropharm.2021.108694_bib57","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1096\/fj.09-152611","article-title":"Fine mapping of AHI1 as a schizophrenia susceptibility gene: from association to evolutionary evidence","volume":"24","author":"Torri","year":"2010","journal-title":"Faseb. J.: official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.neuropharm.2021.108694_bib58","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2016.11.027","article-title":"Phosphodiesterase -7 inhibition affects accumbal and hypothalamic thyrotropin-releasing hormone expression, feeding and anxiety behavior of rats","volume":"319","author":"Vald\u00e9s-Moreno","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2021.108694_bib59","doi-asserted-by":"crossref","first-page":"a021287","DOI":"10.1101\/cshperspect.a021287","article-title":"Adult neurogenesis in neurodegenerative diseases","volume":"7","author":"Winner","year":"2015","journal-title":"Cold Spring Harbor perspectives in biology"},{"issue":"14","key":"10.1016\/j.neuropharm.2021.108694_bib60","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.2174\/138161209788168092","article-title":"Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs","volume":"15","author":"Zhang","year":"2009","journal-title":"Curr. Pharmaceut. Des."},{"issue":"3","key":"10.1016\/j.neuropharm.2021.108694_bib61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138161282103141125124920","article-title":"Targeting phosphodiesterases (PDEs) for treatment of CNS diseases","volume":"21","author":"Zhang","year":"2015","journal-title":"Curr. Pharmaceut. Des."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821002495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:16:52Z","timestamp":1758439012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821002495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":61,"alternative-id":["S0028390821002495"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108694","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108694","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108694"}}